PubRank

Minhyung Lee

Author PubWeight™ 79.06‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Arginine-grafted bioreducible poly(disulfide amine) for gene delivery systems. Biomaterials 2008 1.55
2 Functional enhancement of beta cells in transplanted pancreatic islets by secretion signal peptide-linked exendin-4 gene transduction. J Control Release 2012 1.41
3 Polyethylenimine with acid-labile linkages as a biodegradable gene carrier. J Control Release 2004 1.34
4 Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials 2011 1.22
5 Reducible poly(oligo-D-arginine) for enhanced gene expression in mouse lung by intratracheal injection. Mol Ther 2009 1.11
6 Extracellular HMGB1 released by NMDA treatment confers neuronal apoptosis via RAGE-p38 MAPK/ERK signaling pathway. Neurotox Res 2010 1.10
7 Hypoxia-inducible vascular endothelial growth factor-engineered mesenchymal stem cells prevent myocardial ischemic injury. Mol Ther 2011 1.05
8 Combined angiopoietin-1 and vascular endothelial growth factor gene transfer restores cavernous angiogenesis and erectile function in a rat model of hypercholesterolemia. Mol Ther 2005 1.02
9 Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy. J Control Release 2007 1.02
10 Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis. J Control Release 2005 1.01
11 A guanidinylated bioreducible polymer with high nuclear localization ability for gene delivery systems. Biomaterials 2009 1.00
12 Glucagon-like peptide-1 plasmid construction and delivery for the treatment of type 2 diabetes. Mol Ther 2005 0.99
13 Effect of Terplex/VEGF-165 gene therapy on left ventricular function and structure following myocardial infarction. VEGF gene therapy for myocardial infarction. J Control Release 2003 0.98
14 Protection of insulin secreting cells from nitric oxide induced cellular damage by crosslinked hemoglobin. Biomaterials 2004 0.97
15 Polymeric gene carriers. Crit Rev Eukaryot Gene Expr 2005 0.96
16 GLP-1 gene delivery for the treatment of type 2 diabetes. Mol Ther 2003 0.95
17 Hypoxia-preconditioned adipose tissue-derived mesenchymal stem cell increase the survival and gene expression of engineered neural stem cells in a spinal cord injury model. Neurosci Lett 2010 0.93
18 Polymeric gene carrier for insulin secreting cells: poly(L-lysine)-g-sulfonylurea for receptor mediated transfection. J Control Release 2005 0.93
19 Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model. Mol Ther 2004 0.92
20 Dendrimer type bio-reducible polymer for efficient gene delivery. J Control Release 2012 0.92
21 Enhanced transfection of primary cortical cultures using arginine-grafted PAMAM dendrimer, PAMAM-Arg. J Control Release 2006 0.92
22 Apatite-coated collagen scaffold for bone morphogenetic protein-2 delivery. Tissue Eng Part A 2011 0.92
23 Hypoxia-specific gene expression for ischemic disease gene therapy. Adv Drug Deliv Rev 2009 0.91
24 Poly(L-lactide-co-glycolide) nanospheres conjugated with a nuclear localization signal for delivery of plasmid DNA. J Drug Target 2007 0.90
25 Dexamethasone conjugated poly(amidoamine) dendrimer as a gene carrier for efficient nuclear translocation. Int J Pharm 2006 0.90
26 Deoxycholic acid-conjugated chitosan oligosaccharide nanoparticles for efficient gene carrier. J Control Release 2005 0.89
27 Role of the oxygen-dependent degradation domain in a hypoxia-inducible gene expression system in vascular endothelial growth factor gene therapy. Spine (Phila Pa 1976) 2009 0.89
28 Post-translational regulated and hypoxia-responsible VEGF plasmid for efficient secretion. J Control Release 2012 0.88
29 Hypoxia-inducible vascular endothelial growth factor gene therapy using the oxygen-dependent degradation domain in myocardial ischemia. Pharm Res 2010 0.87
30 Dexamethasone-conjugated polyethylenimine as an efficient gene carrier with an anti-apoptotic effect to cardiomyocytes. J Gene Med 2009 0.87
31 Anti-GAD antibody targeted non-viral gene delivery to islet beta cells. J Control Release 2005 0.86
32 Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice. J Control Release 2006 0.85
33 Nanosphere-mediated delivery of vascular endothelial growth factor gene for therapeutic angiogenesis in mouse ischemic limbs. Biomaterials 2007 0.85
34 Efficient expression of vascular endothelial growth factor using minicircle DNA for angiogenic gene therapy. J Control Release 2007 0.85
35 Hypoxia-inducible expression of vascular endothelial growth factor for the treatment of spinal cord injury in a rat model. J Neurosurg Spine 2007 0.85
36 Efficient GLP-1 gene delivery using two-step transcription amplification plasmid system with a secretion signal peptide and arginine-grafted bioreducible polymer. J Control Release 2011 0.85
37 The effect of evenly distributed load carrying on lower body gait dynamics for normal weight and overweight subjects. Gait Posture 2010 0.85
38 Drug delivery systems for the treatment of ischemic stroke. Pharm Res 2013 0.84
39 Controlled nonviral gene delivery and expression using stable neural stem cell line transfected with a hypoxia-inducible gene expression system. J Gene Med 2010 0.84
40 Targeted gene delivery to ischemic myocardium by homing peptide-guided polymeric carrier. Mol Pharm 2012 0.84
41 Suicide gene therapy using reducible poly (oligo-D-arginine) for the treatment of spinal cord tumors. Biomaterials 2011 0.84
42 Therapeutic effects of a reducible poly (oligo-D-arginine) carrier with the heme oxygenase-1 gene in the treatment of hypoxic-ischemic brain injury. Biomaterials 2010 0.84
43 Local, non-viral IL-12 gene therapy using a water soluble lipopolymer as carrier system combined with systemic paclitaxel for cancer treatment. J Control Release 2005 0.83
44 Erythropoietin gene delivery using an arginine-grafted bioreducible polymer system. J Control Release 2011 0.83
45 Hypoxia as a target for tissue specific gene therapy. J Control Release 2013 0.83
46 Non-viral adiponectin gene therapy into obese type 2 diabetic mice ameliorates insulin resistance. J Control Release 2006 0.83
47 Hypoxia/hepatoma dual specific suicide gene expression plasmid delivery using bio-reducible polymer for hepatocellular carcinoma therapy. J Control Release 2013 0.83
48 Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model. J Control Release 2012 0.83
49 Enhanced protection of Ins-1 beta cells from apoptosis under hypoxia by delivery of DNA encoding secretion signal peptide-linked exendin-4. J Drug Target 2009 0.82
50 Ischemic brain imaging using fluorescent gold nanoprobes sensitive to reactive oxygen species. J Control Release 2013 0.82
51 The effect of biodegradable gelatin microspheres on the neuroprotective effects of high mobility group box 1 A box in the postischemic brain. Biomaterials 2010 0.82
52 Combined delivery of dexamethasone and plasmid DNA in an animal model of LPS-induced acute lung injury. J Control Release 2011 0.82
53 Synergistically combined gene delivery for enhanced VEGF secretion and antiapoptosis. Mol Pharm 2013 0.82
54 Dexamethasone-conjugated low molecular weight polyethylenimine as a nucleus-targeting lipopolymer gene carrier. Bioconjug Chem 2007 0.82
55 Human erythropoietin gene delivery for cardiac remodeling of myocardial infarction in rats. J Control Release 2013 0.82
56 Non-viral systemic delivery of Fas siRNA suppresses cyclophosphamide-induced diabetes in NOD mice. J Control Release 2010 0.81
57 Post-translational regulation of a hypoxia-responsive VEGF plasmid for the treatment of myocardial ischemia. Biomaterials 2013 0.81
58 Comparison of the efficiency and toxicity of sonoporation with branched polyethylenimine-mediated gene transfection in various cultured cell lines. J Drug Target 2008 0.81
59 Hypoxia-inducible plasmid expressing both miSHP-1 and HO-1 for the treatment of ischemic disease. J Control Release 2012 0.81
60 Preparation of large monodispersed spherical silica particles using seed particle growth. J Colloid Interface Sci 2005 0.81
61 Effect of hypoxia-inducible VEGF gene expression on revascularization and graft function in mouse islet transplantation. Transpl Int 2010 0.81
62 Combined gene therapy with hypoxia-inducible factor-1α and heme oxygenase-1 for therapeutic angiogenesis. Tissue Eng Part A 2010 0.81
63 A hypoxia-inducible gene expression system using erythropoietin 3' untranslated region for the gene therapy of rat spinal cord injury. Neurosci Lett 2006 0.80
64 Transcriptional and post-translational regulatory system for hypoxia specific gene expression using the erythropoietin enhancer and the oxygen-dependent degradation domain. J Control Release 2007 0.80
65 Establishment of penile fibrosis model in a rat using mouse NIH 3T3 fibroblasts expressing transforming growth factor beta1. Biol Reprod 2004 0.80
66 Combined delivery of heme oxygenase-1 gene and fibroblast growth factor-2 protein for therapeutic angiogenesis. Biomaterials 2009 0.79
67 Gene therapy with an erythropoietin enhancer-mediated, hypoxia-inducible gene expression system in the corpus cavernosum of mice with high-cholesterol diet-induced erectile dysfunction. J Androl 2012 0.79
68 Molecularly engineered islet cell clusters for diabetes mellitus treatment. Cell Transplant 2012 0.79
69 Gene therapy of neural cell injuries in vitro using the hypoxia-inducible GM-CSF expression plasmids and water-soluble lipopolymer (WSLP). J Control Release 2008 0.79
70 Amphiphilic peptides with arginines and valines for the delivery of plasmid DNA. J Cell Biochem 2011 0.79
71 3,4-dihydroxyphenylalanine-assisted hydroxyapatite nanoparticle coating on polymer scaffolds for efficient osteoconduction. Tissue Eng Part C Methods 2011 0.78
72 Glia/ischemia tissue dual specific gene expression vector for glioblastoma gene therapy. J Control Release 2011 0.78
73 Human erythropoietin gene delivery using an arginine-grafted bioreducible polymer system. Mol Ther 2012 0.78
74 Delivery of hypoxia-inducible VEGF gene to rat islets using polyethylenimine. J Drug Target 2009 0.78
75 Long-circulating DNA-complexed biodegradable multiblock copolymers for gene delivery: degradation profiles and evidence of dysopsonization. J Control Release 2004 0.78
76 Preparation of dexamethasone-based cationic liposome and its application to gene delivery in vitro. J Nanosci Nanotechnol 2011 0.77
77 Development of polymeric gene delivery carriers: PEGylated copolymers of L-lysine and L-phenylalanine. J Drug Target 2007 0.77
78 A comparison of non-viral vectors for gene delivery to pancreatic beta-cells: delivering a hypoxia-inducible vascular endothelial growth factor gene to rat islets. Int J Mol Med 2009 0.77
79 Cross-linked iron oxide nanoparticles for therapeutic engineering and in vivo monitoring of mesenchymal stem cells in cerebral ischemia model. Macromol Biosci 2013 0.77
80 Augmentation of erythropoietin enhancer-mediated hypoxia-inducible gene expression by co-transfection of a plasmid encoding hypoxia-inducible factor 1alpha for ischemic tissue targeting gene therapy. J Drug Target 2008 0.77
81 Dexamethasone-conjugated polyethylenimine/MIF siRNA complex regulation of particulate matter-induced airway inflammation. Biomaterials 2013 0.77
82 Improved transplantation outcome through delivery of DNA encoding secretion signal peptide-linked glucagon-like peptide-1 into mouse islets. Transpl Int 2013 0.76
83 Expression, purification and characterization of TAT-high mobility group box-1A peptide as a carrier of nucleic acids. Biotechnol Lett 2008 0.76
84 Post-translational regulation of gene expression using the ATF4 oxygen-dependent degradation domain for hypoxia-specific gene therapy. J Drug Target 2013 0.76
85 Dexamethasone conjugation to polyamidoamine dendrimers G1 and G2 for enhanced transfection efficiency with an anti-inflammatory effect. J Drug Target 2012 0.76
86 Antiapoptotic Effect of Highly Secreted GMCSF From Neuronal Cell-specific GMCSF Overexpressing Neural Stem Cells in Spinal Cord Injury Model. Spine (Phila Pa 1976) 2015 0.76
87 Effect of glucagon-like peptide-1 gene expression on graft function in mouse islet transplantation. Transpl Int 2011 0.76
88 Synthesis and characterization of dexamethasone-conjugated linear polyethylenimine as a gene carrier. J Cell Biochem 2010 0.76
89 Lung epithelial binding peptide-linked high mobility group box-1 A box for lung epithelial cell-specific delivery of DNA. J Drug Target 2011 0.76
90 A high mobility group B-1 box A peptide combined with an artery wall binding peptide targets delivery of nucleic acids to smooth muscle cells. J Cell Biochem 2009 0.75
91 Combinational therapy of ischemic brain stroke by delivery of heme oxygenase-1 gene and dexamethasone. Biomaterials 2011 0.75
92 Delivery of anti-microRNA-21 antisense-oligodeoxynucleotide using amphiphilic peptides for glioblastoma gene therapy. J Drug Target 2015 0.75
93 Peptide micelle-mediated delivery of tissue-specific suicide gene and combined therapy with avastin in a glioblastoma model. J Pharm Sci 2015 0.75
94 879 Hypoxia-inducible Gene Expression System for Vascular Endothelial Growth Factor Gene Therapy for the Rat Spinal Cord Injury Model. Neurosurgery 2005 0.75
95 Combination of TAT-HMGB1A and R3V6 amphiphilic peptide for plasmid DNA delivery with anti-inflammatory effect. J Drug Target 2014 0.75
96 Plasma-Treated Flexible Aminoclay-Decorated Electrospun Nanofibers for Neural Stem Cell Self-Renewal. J Nanosci Nanotechnol 2016 0.75
97 Amphiphilic peptide carrier for the combined delivery of curcumin and plasmid DNA into the lungs. Biomaterials 2012 0.75
98 Vascular endothelial growth factor-expressing neural stem cell for the treatment of neuropathic pain. Neuroreport 2015 0.75
99 The box A domain of high mobility group box-1 protein as an efficient siRNA carrier with anti-inflammatory effects. J Cell Biochem 2012 0.75
100 Regulatory systems for hypoxia-inducible gene expression in ischemic heart disease gene therapy. Adv Drug Deliv Rev 2011 0.75
101 A new potent hFIX plasmid for hemophilia B gene therapy. Pharm Res 2004 0.75
102 Delivery of hypoxia and glioma dual-specific suicide gene using dexamethasone conjugated polyethylenimine for glioblastoma-specific gene therapy. Mol Pharm 2014 0.75
103 Amphiphilic peptides with arginine and valine residues as siRNA carriers. J Cell Biochem 2012 0.75
104 Thymidine kinase gene delivery using curcumin loaded peptide micelles as a combination therapy for glioblastoma. Pharm Res 2014 0.75
105 VEGF receptor binding peptide-linked amphiphilic peptide with arginines and valines for endothelial cell-specific gene delivery. J Drug Target 2012 0.75
106 Characterization of hydrophobic anti-cancer drug-loaded amphiphilic peptides as a gene carrier. J Cell Biochem 2012 0.75
107 Combined delivery of BCNU and VEGF siRNA using amphiphilic peptides for glioblastoma. J Drug Target 2013 0.75
108 Dexamethasone-loaded peptide micelles for delivery of the heme oxygenase-1 gene to ischemic brain. J Control Release 2011 0.75
109 A Wearable Virtual Chair with the Passive Stability Assist. Conf Proc IEEE Eng Med Biol Soc 2015 0.75
110 Dexamethasone loaded R3V6 peptide micelles for gene delivery. J Control Release 2011 0.75
111 Xenotransplantation of exendin-4 gene transduced pancreatic islets using multi-component (alginate, poly-L-lysine, and polyethylene glycol) microcapsules for the treatment of type 1 diabetes mellitus. J Biomater Sci Polym Ed 2013 0.75
112 VEGF receptor binding peptide-linked high mobility box group-1 box A as a targeting gene carrier for hypoxic endothelial cells. J Cell Biochem 2010 0.75